Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Dealmaking Quarterly Statistics, Q1 2013

A look at the financing, M&A, and alliance activity January-March 2013

Executive Summary

Biopharma financing reached $4.6 billion in Q1 2013, exceeding Q4 2012’s $4.2 billion total, mostly through follow-on public offerings, which made up 47% of the total funding. Conversely, M&A was on the decline with 18 completed transactions together valued at $4.8 billion, the lowest quarter since 2009. The $5.5 billion potential deal value aggregate for alliances more than doubled from the previous quarter, mainly due to Biogen Idec’s $3.25 billion buy of Elan's share of multiple sclerosis drug Tysabri.

Advertisement

Related Content

J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana
Biogen Idec’s Tecfidera Goes To Market With Claim For Delay Of Disability Progression
Biogen Leans On Plegridy To Help Extend The Life Of Avonex
Onyx’s Transformative Year: From Productive Partner To Big Cap Contender?
Flush With Cash, Tesaro Advances Rolapitant Toward NDA
Reckitt Deals Feed OTC Domination Plan
Elan Prepares For A Buying Spree Now That Biogen Has Taken Over Tysabri
The Medicines Co. Enters PCSK9 Race With Alnylam Deal
Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment
venBio Rings In 2013 With Two Company Launches

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel